# A Safety and Efficacy Study of T0903131 (INT131) Besylate to Treat Type 2 Diabetes Mellitus

> **NCT00952445** · PHASE2 · COMPLETED · sponsor: **InteKrin Therapeutics, Inc.** · enrollment: 70 (actual)

## Conditions studied

- Diabetes Mellitus, Type II

## Interventions

- **DRUG:** T0903131 Besylate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00952445
- **Lead sponsor:** InteKrin Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** —
- **Final completion:** 2004-06
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2022-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00952445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00952445, "A Safety and Efficacy Study of T0903131 (INT131) Besylate to Treat Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00952445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*